Penn Medicine, University of Pennsylvania Health System’s Post

✨YOU FUNDED IT!✨ We are proud to announce the funding of 4 new cancer research projects and 2 clinical trials at Siteman Cancer Center. The projects and trials will benefit from nearly $1.4 million in new grants awarded through the Siteman Investment Program. Research focused on breast and ovarian cancer development, chemoradiation therapy for cervical cancer, immunotherapy for leukemia and enhancing the well-being of family caregivers of cancer hospice patients are included in these projects. One clinical trial focuses on improving the efficacy of a personalized cancer vaccine for patients with glioblastoma, which is the deadliest brain tumor in adults. 🔗 Learn more: https://bit.ly/3WF6lDz

In the 2023 Faces of Lung Cancer Report, Dr. Cheryl Ho, Medical Oncologist at BC Cancer, dives into the most recent advances in targeted therapy treatment landscape for those with early-stage disease. "The future is promising for patients with early-stage lung cancer. The improvements in the implementation of lung cancer screening, combined with the latest breakthroughs in targeted therapy and immunotherapy, offer patients an opportunity for a cure. These advancements mean patients can lead a normal life where they can pursue their dreams and aspirations without the constant shadow of cancer.” Read the full report now at https://bit.ly/3sXf4pH

If you are a cancer patient with a solid tumor which doesn’t respond to immunotherapies (“cold” tumors), such as prostate, breast, and pancreatic cancer patients, can you access immunotherapies, which hold the promise of amazing results? Gary Onik, MD, a physician, researcher, medical device inventor, and a cancer patient and survivor, has developed several innovative techniques and instrumentation to treat cancer, including a unique approach to immunotherapy that creates a cancer vaccine within the patient’s body. The “Onik Method” stimulates the immune system to do what it is supposed to do: recognize and eliminate the tumor. This approach enables immunotherapy for "cold" tumors that usually do not respond to traditional immunotherapy. He successfully treated his own terminal prostate cancer using this invention. To find out more, please see https://lnkd.in/e8p5trPS

The 2023 impact report by Conquer Cancer, the ASCO Foundation https://lnkd.in/gg4KtnwQ #oncodaily #oncology #cancer #oncologyresearch #cancerresearch #impactreport #researchimpact #lifesavingresearch #donationimpact #cancerawareness

June is Cancer Immunotherapy Month and shines a spotlight on how immunotherapy approaches are revolutionizing cancer treatment. In the last decade alone, advancements in cancer immunotherapy, such as CAR-T therapy, have significantly changed the treatment options and survival outcomes for patients with a range of cancers. Even in the last six months, substantial progress has been made with the FDA’s approval of the first-ever cell therapy for solid tumors. With these major strides in the field paving the path for future innovation and novel treatments, we are greatly encouraged as we gear up to begin a registration-enabling Phase 2/3 trial for our lead cell therapy candidate, IMA203, in metastatic melanoma patients. What does immunotherapy look like at Immatics? Check out this video that summarizes our therapeutic approach here: https://lnkd.in/d2_Bzrrj #Immune2Cancer #Immunotherapy #Immunooncology #Celltherapy #Cancer #Bispecifics

It’s 20 years since the discovery of the EGFR mutation - a milestone in the fight against lung cancer. This discovery has revolutionised the treatment of EGFR+ lung cancer, offering hope and improved outcomes for patients. As we celebrate the incredible advancements, we also take time to remember those we’ve lost. Read more about this transformative discovery here: https://lnkd.in/eT-pTqXS #EGFR #LungCancer #CancerResearch #PatientAdvocacy

Turner Industries has made cancer screening a priority for its employees. In 2020, the company began implementation of a strategic plan to improve their employees' breast cancer and colorectal cancer screening rates. Within a year after launching this initiative, Turner Industries saw a 39.1% increase in breast cancer screening rates and a 22.8% increase in overall colorectal cancer screening rates. This is just the beginning. With forward-thinking leaders like Turner Industries and others, we can change the cancer narrative in our state. https://bit.ly/3LPEr2v

#ESMOBreast25: 🌍 Ready to make a global impact in breast cancer research? Submit your abstract and be part of the change– Deadline 11 February 2025. 🗓️ Event Dates: 14 –17 May 2025 📍 Location: Munich, Germany and Online 🔗 https://ow.ly/cQr550TA0c6 At this event you will be able to: ➡️ Update your knowledge on the fast-developing field of breast cancer; ➡️ Understand recent developments in novel diagnostics, biomarkers, and treatments among the different subtypes of breast cancer; ➡️ Gain insights on risk-adapted strategies for optimising treatment of breast cancer; ➡️ Learn the latest on the impact of antibody drug conjugates and immunotherapy on treatment landscape for breast cancer; ➡️ Understand special considerations for different subgroups of patients with breast cancer.

Key role of immunotherapy in Breast Cancer

Cancer Immunotherapy Market Overview The global cancer immunotherapymarket is estimated to be worth over USD 345.19 Bnin 2033 and is expected to grow at CAGR of12.5% during the forecast period (2024-2033).Cancer immunotherapy is an innovative method that harnesses the body's immune system to combat cancer, indicating a significantradical change in oncology.Conventional cancer treatments, such as chemotherapy and radiation, especially target cancer cells directly but often at the cost of serious damage to healthy tissues. Immunotherapy, regardless, harnesses and improves the innate capacity of the immune system to discern and eradicate cancer cells, offering a more targeted and often more benign approach. Free PDF for Complete Information - https://lnkd.in/gAjaNxcY